Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ACHV NYSE:EBS NASDAQ:MYGN NASDAQ:VSTM On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACHVAchieve Life Sciences$2.98-5.7%$2.69$1.84▼$5.31$152.28M1.531.23 million shs1.46 million shsEBSEmergent Biosolutions$8.29-1.3%$7.46$4.02▼$12.73$442.01M2.031.41 million shs898,751 shsMYGNMyriad Genetics$6.37+2.4%$5.26$3.76▼$29.30$592.67M1.922.38 million shs2.58 million shsVSTMVerastem$9.25+0.2%$6.18$2.34▼$9.43$569.25M0.922.94 million shs1.46 million shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACHVAchieve Life Sciences0.00%+2.05%+16.86%-23.59%-32.12%EBSEmergent Biosolutions0.00%-10.29%+47.16%+31.51%-0.30%MYGNMyriad Genetics0.00%+5.81%+62.92%+42.83%-77.52%VSTMVerastem0.00%+1.87%+52.14%+53.65%+270.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationACHVAchieve Life Sciences2.0015 of 5 stars3.82.00.00.02.20.00.6EBSEmergent Biosolutions4.6476 of 5 stars3.51.00.04.63.32.52.5MYGNMyriad Genetics3.8777 of 5 stars3.12.00.04.13.11.70.6VSTMVerastem3.0406 of 5 stars3.53.00.00.03.12.50.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceACHVAchieve Life Sciences 3.50Strong Buy$14.67392.17% UpsideEBSEmergent Biosolutions 3.00Buy$14.3373.00% UpsideMYGNMyriad Genetics 2.21Hold$12.4595.52% UpsideVSTMVerastem 3.00Buy$13.2943.63% UpsideCurrent Analyst Ratings BreakdownLatest ACHV, MYGN, VSTM, and EBS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/25/2025VSTMVerastemB. RileySubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy8/21/2025ACHVAchieve Life SciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$12.008/12/2025VSTMVerastemZacks ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold8/8/2025VSTMVerastemRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$12.00 ➝ $13.006/25/2025VSTMVerastemRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeOutperform ➝ Moderate Buy$16.00 ➝ $12.00(Data available from 9/1/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookACHVAchieve Life SciencesN/AN/AN/AN/A$0.61 per shareN/AEBSEmergent Biosolutions$1.04B0.42$1.92 per share4.32$8.91 per share0.93MYGNMyriad Genetics$837.60M0.71$1.00 per share6.38$7.70 per share0.83VSTMVerastem$10K56,924.50N/AN/A($0.65) per share-14.23Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateACHVAchieve Life Sciences-$39.83M-$1.46N/AN/AN/AN/A-193.49%-116.68%11/6/2025 (Estimated)EBSEmergent Biosolutions-$190.60M$2.453.384.00N/A16.38%24.63%8.97%11/5/2025 (Estimated)MYGNMyriad Genetics-$127.30M-$4.28N/AN/AN/A-47.45%-5.17%-3.44%11/6/2025 (Estimated)VSTMVerastem-$130.64M-$3.28N/AN/AN/AN/A-2,003.62%-119.85%11/5/2025 (Estimated)Latest ACHV, MYGN, VSTM, and EBS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/7/2025Q2 2025ACHVAchieve Life Sciences-$0.37-$0.37N/A-$0.37N/AN/A8/7/2025Q2 2025VSTMVerastem-$0.64-$0.39+$0.25-$0.39$6.01 million$2.14 million8/6/2025Q2 2025EBSEmergent Biosolutions-$0.26$0.16+$0.42-$0.22$148.55 million$140.90 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthACHVAchieve Life SciencesN/AN/AN/AN/AN/AEBSEmergent BiosolutionsN/AN/AN/AN/AN/AMYGNMyriad GeneticsN/AN/AN/AN/AN/AVSTMVerastemN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioACHVAchieve Life Sciences0.216.646.64EBSEmergent Biosolutions1.255.663.00MYGNMyriad GeneticsN/A1.421.28VSTMVerastem2.063.463.44Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipACHVAchieve Life Sciences33.52%EBSEmergent Biosolutions78.40%MYGNMyriad Genetics99.02%VSTMVerastem88.37%Insider OwnershipCompanyInsider OwnershipACHVAchieve Life Sciences3.00%EBSEmergent Biosolutions3.20%MYGNMyriad Genetics2.10%VSTMVerastem2.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableACHVAchieve Life Sciences2051.10 million49.57 millionOptionableEBSEmergent Biosolutions2,42053.35 million51.64 millionOptionableMYGNMyriad Genetics2,70093.04 million91.09 millionOptionableVSTMVerastem5061.54 million60.25 millionOptionableACHV, MYGN, VSTM, and EBS HeadlinesRecent News About These CompaniesVerastem (NASDAQ:VSTM) Sets New 1-Year High - What's Next?August 30 at 6:05 AM | marketbeat.comB. Riley Upgrades Verastem (NASDAQ:VSTM) to Strong-BuyAugust 29 at 8:41 AM | marketbeat.comVerastem (NASDAQ:VSTM) Upgraded at B. RileyAugust 28, 2025 | americanbankingnews.comVerastem Oncology to Present at Upcoming Investor ConferencesAugust 27, 2025 | mms.businesswire.comVerastem, Inc. $VSTM Shares Sold by Stonepine Capital Management LLCAugust 26, 2025 | marketbeat.comVerastem’s Promising Phase 3 Trial in Ovarian Cancer: A Potential Game-Changer?August 25, 2025 | tipranks.comBalyasny Asset Management L.P. Increases Stake in Verastem IncAugust 20, 2025 | gurufocus.comVerastem, Inc. (NASDAQ:VSTM) Receives Average Recommendation of "Moderate Buy" from AnalystsAugust 18, 2025 | marketbeat.comZacks Research Upgrades Verastem (NASDAQ:VSTM) to "Hold"August 17, 2025 | marketbeat.comVerastem Advances with Phase 3 Trial Progress and Product Launch Boosting ProspectsAugust 17, 2025 | insidermonkey.comVerastem Advances with Phase 3 Trial Progress and Product Launch Boosting ProspectsAugust 17, 2025 | finance.yahoo.comVerastem price target lowered to $14 from $16 at MizuhoAugust 15, 2025 | msn.comVerastem stock soars after KRAS inhibitor shows strong lung cancer resultsAugust 14, 2025 | za.investing.comVerastem Unveils Promising VS-7375 Study ResultsAugust 14, 2025 | msn.comVerastem Oncology Announces Late-Breaking Abstract from Partner GenFleet Therapeutics' Study in China of GFH375 (VS-7375) in Advanced Non-Small Cell Lung Cancer at IASLC 2025 World Conference on Lung CancerAugust 13, 2025 | businesswire.comVerastem Inc. Earnings Call: Positive Outlook with Key AchievementsAugust 13, 2025 | msn.comVerastem, Inc. (NASDAQ:VSTM) Q2 2025 Earnings Call TranscriptAugust 12, 2025 | msn.comWall Street Zen Upgrades Verastem (NASDAQ:VSTM) to "Hold"August 11, 2025 | marketbeat.comVerastem (NASDAQ:VSTM) Releases Quarterly Earnings ResultsAugust 10, 2025 | marketbeat.comVerastem (NASDAQ:VSTM) Price Target Raised to $13.00August 10, 2025 | marketbeat.comVerastem, Inc. (VSTM) Q2 2025 Earnings Call TranscriptAugust 8, 2025 | seekingalpha.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeACHV, MYGN, VSTM, and EBS Company DescriptionsAchieve Life Sciences NASDAQ:ACHV$2.98 -0.18 (-5.70%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$3.04 +0.06 (+1.85%) As of 08/29/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Achieve Life Sciences, Inc., a clinical-stage pharmaceutical company, develops and commercializes cytisinicline for smoking cessation and nicotine addiction. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms. It has license and supply agreement with Sopharma AD and University of Bristol Achieve Life Sciences, Inc. is based in Vancouver, Canada.Emergent Biosolutions NYSE:EBS$8.28 -0.11 (-1.25%) Closing price 08/29/2025 03:59 PM EasternExtended Trading$8.33 +0.05 (+0.56%) As of 08/29/2025 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Emergent BioSolutions Inc., a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax. It also provides ACAM2000, a smallpox vaccine; CNJ-016 to address complications from smallpox vaccination; TEMBEXA for the treatment of smallpox disease caused by variola virus in adult and pediatric patients; BAT for the treatment of symptomatic botulism; Ebanga for the treatment of Ebola; Reactive Skin Decontamination Lotion Kit to remove or neutralize chemical warfare agents from the skin; Trobigard, a atropine sulfate obidoxime chloride auto-injector. In addition, the company is developing CGRD-001 for the treatment of poisoning by organophosphorus nerve agents or organophosphorus compounds; EBS-LASV to prevent Lassa fever; EBS-MARV to prevent Marburg virus disease; EBS-SUDV to prevent Sudan virus disease; Pan-Ebola mAbs for the treatment of ebola virus; SIAN Antidote for initial treatment of certain or suspected acute cyanide poisoning; UniFlu for immunity against influenza A and B viruses; and WEVEE-VLP for equine encephalitis virus infections. Further, it provides contract development and manufacturing services comprising drug substance and product manufacturing, and packaging, as well as technology transfer, process, and analytical development services. The company was incorporated in 1998 and is headquartered in Gaithersburg, Maryland.Myriad Genetics NASDAQ:MYGN$6.37 +0.15 (+2.41%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$6.37 0.00 (-0.02%) As of 08/29/2025 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Myriad Genetics, Inc., a genetic testing and precision medicine company, develops genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and pharmacogenomics. It also provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer. The company also offers Prolaris Prostate Cancer Prognostic Test, an RNA expression tumor analysis for assessing the aggressiveness of prostate cancer; EndoPredict Breast Cancer Prognostic Test, an RNA expression test for assessing the aggressiveness of breast cancer; Precise Tumor, a solution for precision oncology; and Prequel Prenatal Screen, a non-invasive prenatal screening test conducted using maternal blood to screen for severe chromosomal disorders in a fetus. It provides Foresight Carrier Screen, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; SneakPeek, a non-invasive blood test that predicts the gender of a fetus; and GeneSight Psychotropic Mental Health Medication Test, a DNA genotyping test to aid psychotropic drug selection for patients suffering from depression, anxiety, attention-deficit, hyperactivity disorder, and other mental health conditions. It has a strategic collaboration with Illumina, Inc., Memorial Sloan Kettering Cancer Center, the University of Texas MD Anderson Cancer Center, SimonMed, and Onsite Women's Health. Myriad Genetics, Inc. was incorporated in 1992 and is headquartered in Salt Lake City, Utah.Verastem NASDAQ:VSTM$9.25 +0.02 (+0.22%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$9.18 -0.07 (-0.80%) As of 08/29/2025 07:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Verastem, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States. Its product candidates are Avutometinib, an orally available small molecule RAF/MEK clamp that inhibits the ras sarcoma RAF/MEK, ERK mitogen activated pathway kinase pathway which is involved in cell proliferation, migration, transformation, and survival of tumor cells; and Defactinib, an oral small molecule inhibitor of FAK and proline-rich tyrosine kinase for various solid tumors. The company is involved in clinical studies, including RAMP 301, a randomized global confirmatory trial to evaluate the combination of Avutometinib and Defactinib for the treatment of patients with recurrent low-grade serous ovarian cancer; RAMP 201, an adaptive two-part multicenter, parallel cohort, randomized open label trial to evaluate the efficacy and safety of Avutometinib and in combination with Defactinib; and FRAME, an investigation of Avutometinib and Defactinib in patients with KRAS mutant cancers and subsequent analyses; and RAMP 204 and 205. It has license agreements with Chugai Pharmaceutical Co., Ltd. for the development, commercialization, and manufacture of products containing Avutometinib; and Pfizer Inc. to research, develop, manufacture, and commercialize products containing Pfizer's inhibitors of FAK for therapeutic, diagnostic, and prophylactic uses in humans. In addition, it has a clinical collaboration agreement with Amgen, Inc. to evaluate the combination of Avutometinib with Amgen's KRAS-G12C inhibitor LUMAKRAS which in Phase 1/2 trial entitled RAMP 203; and a discovery and development collaboration with GenFleet Therapeutics to advance new programs targeting RAS pathway-driven cancers. Verastem, Inc. was incorporated in 2010 and is headquartered in Needham, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 08/25 - 08/29 Ollie’s Bargain Outlet: Buy it While It’s Still a Bargain Tencent Music Stock Outshines Spotify as China’s Music Giant With Shares Near Highs, Here's to Watch in Broadcom's Q3 Report Best Buy Marketplace: Potential Growth Catalyst or Risky Gimmick? DICKS’s Sporting Goods Stock Dropped After Earnings—Is It a Buy? CrowdStrike at a Crossroads: AI Halo vs. Risks Snowflake’s Snowballing Business and Robust Stock Price Outlook Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
